We are live on ! Find out more
ERNA icon

Eterna Therapeutics
ERNA

13 hedge funds and large institutions have $982K invested in Eterna Therapeutics in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more capital invested

Capital invested by funds: $637K → $982K (+$345K)

44% more funds holding

Funds holding: 9 → 13 (+4)

0% more ownership

Funds ownership: 0.02% → 0.02% (+0%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
13
Holders Change
+4
Holders Change %
+44.44%
% of All Funds
0.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
1
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCA
Sippican Capital Advisors
Massachusetts
+$34.5K
2
AWE
Avidian Wealth Enterprises
Texas
+$26.9K
3
Citadel Advisors
Citadel Advisors
Florida
+$18.6K
4
Renaissance Technologies
Renaissance Technologies
New York
+$18.6K
5
UBS Group
UBS Group
Switzerland
+$1.38K

Top Sellers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
-$690
2
PWA
Provenance Wealth Advisors
Florida
-$27
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$2

ERNA Hedge Fund Activity: Q1 2024 in Review

13 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q1 2024, worth a combined $982K — up 54% from $637K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new ERNA positions and 0 closed out — a net gain of 4 holders — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Sippican Capital Advisors, adding an estimated $34.5K. The largest seller was Tower Research Capital (TRC), cutting an estimated $690.

  • 13 institutional investors held Eterna Therapeutics (ERNA) as of Q1 2024, up from 9 in Q4 2023.
  • Funds reported $982K of Eterna Therapeutics stock for Q1 2024, up 54% quarter-over-quarter.
  • 4 funds opened new Eterna Therapeutics positions in Q1 2024 and 0 closed out, a net change of +4 holders.
  • The largest Eterna Therapeutics buyer in Q1 2024 was Sippican Capital Advisors, an estimated $34.5K added.
  • The largest Eterna Therapeutics seller in Q1 2024 was Tower Research Capital (TRC), an estimated $690 sold.

Based on aggregated 13F filings for Q1 2024.